NASDAQ:VRTX   Vertex Pharmaceuticals Incorporated
All risks already in price IMO. Short downtrend most probably soon will change to bullish as fundamental improves.
Triger: latest news about ABBV & Galapagos Phase 2 study in CF
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。